Browsing by Author "Mihailovic, Smiljana (57192397265)"
Now showing 1 - 4 of 4
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication GSTO1*CC genotype (Rs4925) predicts shorter survival in clear cell renal cell carcinoma male patients(2019) ;Radic, Tanja (35275858300) ;Coric, Vesna (55584570400) ;Bukumiric, Zoran (36600111200) ;Pljesa-Ercegovac, Marija (16644038900) ;Djukic, Tatjana (36193753800) ;Avramovic, Natasa (23134505800) ;Matic, Marija (58618962300) ;Mihailovic, Smiljana (57192397265) ;Dragicevic, Dejan (6506794751) ;Dzamic, Zoran (6506981365) ;Simic, Tatjana (6602094386)Savic-Radojevic, Ana (16246037100)Omega class glutathione transferases, GSTO1-1 and GSTO2-2, exhibit different activities involved in regulation of inflammation, apoptosis and redox homeostasis. We investigated the the prognostic significance of GSTO1 (rs4925) and GSTO2 (rs156697 and rs2297235) polymorphisms in clear cell renal cell carcinoma (ccRCC) patients. GSTO1-1 and GSTO2-2 expression and phosphorylation status of phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/ /mammalian target of rapamycin (mTOR) and Raf/MEK/extracellular signal-regulated kinase (ERK) signaling pathways in non-tumor and tumor ccRCC tissue, as well as possible association of GSTO1-1 with signaling molecules were also assessed. GSTO genotyping was performed by quantitative PCR in 228 ccRCC patients, while expression and immunoprecipitation were analyzed by Western blot in 30 tissue specimens. Shorter survival in male carriers of GSTO1*C/C wild-type genotype compared to the carriers of at least one variant allele was demonstrated (p = 0.049). GSTO1*C/C genotype independently predicted higher risk of overall mortality among male ccRCC patients (p = 0.037). Increased expression of GSTO1-1 and GSTO2-2 was demonstrated in tumor compared to corresponding non-tumor tissue (p = 0.002, p = 0.007, respectively), while GSTO1 expression was correlated with interleukin-1β (IL-1β)/pro-interleukin-1β (pro-IL-1β) ratio (r = 0.260, p = 0.350). Interaction of GSTO1 with downstream effectors of investigated pathways was shown in ccRCC tumor tissue. This study demonstrated significant prognostic role of GSTO1 polymorphism in ccRCC. Up-regulated GSTO1-1 and GSTO2-2 in tumor tissue might contribute to aberrant ccRCC redox homeostasis. © 2019 by the authors. Licensee MDPI, Basel, Switzerland. - Some of the metrics are blocked by yourconsent settings
Publication GSTO1*CC genotype (Rs4925) predicts shorter survival in clear cell renal cell carcinoma male patients(2019) ;Radic, Tanja (35275858300) ;Coric, Vesna (55584570400) ;Bukumiric, Zoran (36600111200) ;Pljesa-Ercegovac, Marija (16644038900) ;Djukic, Tatjana (36193753800) ;Avramovic, Natasa (23134505800) ;Matic, Marija (58618962300) ;Mihailovic, Smiljana (57192397265) ;Dragicevic, Dejan (6506794751) ;Dzamic, Zoran (6506981365) ;Simic, Tatjana (6602094386)Savic-Radojevic, Ana (16246037100)Omega class glutathione transferases, GSTO1-1 and GSTO2-2, exhibit different activities involved in regulation of inflammation, apoptosis and redox homeostasis. We investigated the the prognostic significance of GSTO1 (rs4925) and GSTO2 (rs156697 and rs2297235) polymorphisms in clear cell renal cell carcinoma (ccRCC) patients. GSTO1-1 and GSTO2-2 expression and phosphorylation status of phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/ /mammalian target of rapamycin (mTOR) and Raf/MEK/extracellular signal-regulated kinase (ERK) signaling pathways in non-tumor and tumor ccRCC tissue, as well as possible association of GSTO1-1 with signaling molecules were also assessed. GSTO genotyping was performed by quantitative PCR in 228 ccRCC patients, while expression and immunoprecipitation were analyzed by Western blot in 30 tissue specimens. Shorter survival in male carriers of GSTO1*C/C wild-type genotype compared to the carriers of at least one variant allele was demonstrated (p = 0.049). GSTO1*C/C genotype independently predicted higher risk of overall mortality among male ccRCC patients (p = 0.037). Increased expression of GSTO1-1 and GSTO2-2 was demonstrated in tumor compared to corresponding non-tumor tissue (p = 0.002, p = 0.007, respectively), while GSTO1 expression was correlated with interleukin-1β (IL-1β)/pro-interleukin-1β (pro-IL-1β) ratio (r = 0.260, p = 0.350). Interaction of GSTO1 with downstream effectors of investigated pathways was shown in ccRCC tumor tissue. This study demonstrated significant prognostic role of GSTO1 polymorphism in ccRCC. Up-regulated GSTO1-1 and GSTO2-2 in tumor tissue might contribute to aberrant ccRCC redox homeostasis. © 2019 by the authors. Licensee MDPI, Basel, Switzerland. - Some of the metrics are blocked by yourconsent settings
Publication Impact of transient period of metabolic adaptation on perinatal asphyxia in neonates with intrauterine growth retardation(2017) ;Mitrovic, Tanja Lazic (36191969100) ;Mikovic, Zeljko (7801694296) ;Markovic, Vesna Mandic (57218618497)Mihailovic, Smiljana (57192397265)Introduction: Temperature, glycemia and respiration make neonatal energy triangle (NET). In growth retardation (IUGR) neonates pathological metabolic adaptation exists in transient neonatal period. Aim: The of this study was to examine the occurrence of pathological NET and check its impact on perinatal asphyxia during the transient period in IUGR neonates. Material and methods: One hundred and fifty-nine neonates with IUGR were classified into early preterm, late preterm and term neonates. By the presence of hypothermia, hypoglycemia and hypoxia in the first hour after birth neonates were classified into: group of pathological NET, group of unstable NET and group of stable NET. We analyzed distribution per body mass, gestational age, type of IUGR, gender and the frequency of perinatal asphyxia between the groups. Results: The late preterm neonates were the most frequent in the group of pathological NET. Perinatal asphyxia was diagnosed in 52 (32.7%) neonates, with highest frequency in the group of pathological NET. Univariate binary logistic regression analysis showed that pathological NET in neonates with IUGR is significant predictor for perinatal asphyxia occurrence (OR = 8.57; CI = 4.05-18.12; p < 0.001 R2 = 0.27). Conclusion: Poor metabolic adaptation in neonates with IUGR in the first hour after birth is significant risk factor for the perinatal asphyxia. © 2016 Informa UK Limited, trading as Taylor & Francis Group. - Some of the metrics are blocked by yourconsent settings
Publication The Association of Polymorphisms in Genes Encoding Antioxidant Enzymes GPX1 (rs1050450), SOD2 (rs4880) and Transcriptional Factor Nrf2 (rs6721961) with the Risk and Development of Prostate Cancer(2022) ;Djokic, Milica (57215827890) ;Radic, Tanja (35275858300) ;Santric, Veljko (55598984100) ;Dragicevic, Dejan (6506794751) ;Suvakov, Sonja (36572404500) ;Mihailovic, Smiljana (57192397265) ;Stankovic, Vesna (56186752300) ;Cekerevac, Milica (18433619600) ;Simic, Tatjana (6602094386) ;Nikitovic, Marina (6602665617)Coric, Vesna (55584570400)Background and Objectives: Mounting evidence implicates oxidative damage in prostate carcinogenesis, contributing to modifications of macromolecules that drive cellular malignant transformation. Functional single-nucleotide polymorphisms (SNPs) of enzymes involved in redox homeostasis can disrupt pro-oxidant–antioxidant balance, leading to accumulation of reactive oxygen species and oxidative damage. We investigated the potential role of genetic polymorphisms of antioxidant enzymes glutathione peroxidase 1 (GPX1 rs1050450) and superoxide dismutase 2 (SOD2 rs4880) and regulatory antioxidant protein nuclear factor erythroid 2-related factor 2 (Nrf2 rs6721961) in the susceptibility to prostate cancer development (PC) and prognosis. Materials and Methods: We conducted a case–control study consisting of 235 patients with PC and 240 controls. Gene polymorphisms were determined by quantitative polymerase chain reaction (qPCR) and polymerase chain reaction with confronting two-pair primers (PCR-CTTP) methods. Multiple risk models were composed to inspect the separate and mutual effect of multiple genes and in combination with acquired contributory factors on the risk of PC development. Results: Independently, carriers of at least one SOD2*C allele had increased risk of PC development, which was significantly further amplified in advanced statistical models. When tested in combination, individuals with both SOD2*C allele and Nrf2*C/C genotype were also at increased risk of PC development, which was augmented when combined with acquired contributory factors. During the mean 75 ± 25 months of follow-up, investigated gene polymorphisms did not affect overall survival. Conclusion: Our results suggest that these gene polymorphisms could be used as risk biomarkers of PC evolution. © 2022 by the authors.